Seasoned pharmaceutical executive with extensive experience in high-growth life sciences companies joins NervGen Leadership appointment supports the company’s mission to advance NVG-291 after the completion of the ongoing Phase 1b/2a… Read More
Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research,… Read More
TRODELVY has now improved survival in both pre-treated HR+/HER2- metastatic breast cancer and in second-line metastatic triple-negative breast cancer MISSISSAUGA, ON – Gilead Sciences Canada, Inc. (Gilead Canada) announced that Health… Read More
John has over 30 years of experience in clinical project management, clinical and regulatory strategies, and clinical operations within CROs and sponsor companies. He is well experienced in all phases… Read More
LAVAL, QC – Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon (“JJ”) will join the Company… Read More
